Candel Therapeutics Inc (CADL): Next-Year EPS Estimate 25.52%
As of 2026-07-17, Candel Therapeutics Inc (CADL) has a next-year EPS growth estimate of 25.52%. Featured in our EPS revision report on 2026-06-30.
On 2026-07-13, analyst consensus for CADL's next-year EPS growth shifted from 38.14% to 25.52% — a negative change of 12.62 percentage points. The revised estimate has been sustained across 5 subsequent trading sessions. Current-year growth is projected at -29.33%.
What's Driving This
Despite a 12.62 pp downgrade in next-year EPS growth estimates (from 38.14% to 25.52%), CADL stock has risen on positive clinical momentum. The primary driver is the extended benefit data from the Phase 3 trial of CAN-2409 in prostate cancer, reported at AUA 2026
Generated 2026-07-14 from news as of 2026-07-14
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 25.52%
- EPS growth this year
- -29.33%
- EPS next quarter (est)
- -$0.23
- Last price
- $10.18
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-07-17 | 25.52% | -29.33% | -$0.23 | $10.18 |
| 2026-07-16 | 25.52% | -29.33% | -$0.23 | $9.48 |
| 2026-07-15 | 25.52% | -29.33% | -$0.23 | $9.64 |
| 2026-07-14 | 25.52% | -29.33% | -$0.23 | $9.87 |
| 2026-07-13 | 25.52% | -29.33% | -$0.23 | $9.64 |
| 2026-07-12 | 38.14% | -28.17% | -$0.23 | $9.49 |
| 2026-07-09 | 38.14% | -28.17% | -$0.23 | $9.89 |
| 2026-07-08 | 38.14% | -28.17% | -$0.23 | $9.88 |
| 2026-07-07 | 38.14% | -28.17% | -$0.23 | $9.85 |
| 2026-07-06 | 38.14% | -28.17% | -$0.23 | $10.03 |
| 2026-07-05 | 38.14% | -28.17% | -$0.23 | $9.83 |
| 2026-07-02 | 38.14% | -28.17% | -$0.23 | $9.83 |
| 2026-07-01 | 38.14% | -28.17% | -$0.23 | $9.88 |
| 2026-06-30 | 38.14% | -28.17% | -$0.23 | $10.30 |
| 2026-06-29 | 38.14% | -28.17% | -$0.23 | $10.36 |
| 2026-06-28 | 38.14% | -28.17% | -$0.23 | $9.79 |
| 2026-06-25 | 38.14% | -28.17% | -$0.23 | $9.47 |
| 2026-06-24 | 38.14% | -28.17% | -$0.23 | $9.27 |
| 2026-06-23 | 38.14% | -28.17% | -$0.23 | $9.08 |
| 2026-06-22 | 38.14% | -28.17% | -$0.23 | $9.15 |
| 2026-06-21 | 38.14% | -28.17% | -$0.23 | $8.31 |
| 2026-06-18 | 28.85% | -30.37% | -$0.24 | $8.31 |
| 2026-06-17 | 28.85% | -30.37% | -$0.24 | $7.99 |
| 2026-06-16 | 28.85% | -30.37% | -$0.24 | $7.97 |
| 2026-06-15 | 28.85% | -30.37% | -$0.24 | $8.56 |
| 2026-06-14 | 28.85% | -30.37% | -$0.24 | $8.56 |
| 2026-06-11 | 38.14% | -28.17% | -$0.23 | $8.16 |
| 2026-06-10 | 28.85% | -30.37% | -$0.24 | $8.35 |
| 2026-06-09 | 28.85% | -30.37% | -$0.24 | $8.67 |
| 2026-06-08 | 28.85% | -30.37% | -$0.24 | $8.50 |
Reports Featuring CADL
Recent News
- Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual MeetingGlobeNewswire
- Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswire
Screen Performance
Aggregate stats across all 1864 tickers our top-EPS-revision screen has flagged over the past 107 days.
- Median return since detection
- +2.5%
- % of tickers in the green
- 55%
- Median return on winners
- +20.8%
- Large revisions captured
- 1048
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Candel Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-07-17, Candel Therapeutics Inc (CADL) has a next-year EPS growth estimate of 25.52%, based on analyst consensus.
When was the latest EPS estimate revision for CADL?▾
The most recent revision occurred on 2026-07-13, when analysts adjusted the next-year EPS growth estimate from 38.14% to 25.52%.
What sector and industry does Candel Therapeutics Inc belong to?▾
Candel Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. CADL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Candel Therapeutics Inc (CADL) appears here because it was detected by our daily top-EPS-revision-performer screen.